Arrowhead Subsidiary, Insert Therapeutics, to Present at Institutional Investor Conference
PASADENA, California – May 17, 2007 – Arrowhead Research Corporation (Nasdaq: ARWR) announced today that Edward Jacobs, Chief Executive Officer and President of Insert Therapeutics, a majority owned subsidiary of Arrowhead, will present at the May 18th Annual Institutional Investor Conference at the Princeton Club in New York City on May 22, 2007. Mr. Jacobs' presentation entitled "Insert Therapeutics Product Development Update" will highlight Insert's progress in using its proprietary polymeric transport system, Cyclosert™, to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert's lead drug candidate, a combination of its linear, cylodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006.
Mr. Jacobs has been the Chief Executive Officer of Insert Therapeutics since January 2007. Prior to joining Insert, he held CEO positions at a number of life science companies and has more than 20 years of executive level pharma and biotech experience, with particular emphasis in the oncology space, as well as strategic planning and marketing. He has successfully led several biotech companies to acquisition by major pharmaceutical companies and secured substantial collaborations and licensing deals.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
About Insert Therapeutics, Inc.
Insert Therapeutics, Inc. (www.insertt.com), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert™, to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert’s affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts
Virginia Dadey; Vice President, Investor Relations
Telephone: 212.541.3707
Email: vdadey@arrowres.com